Moberg Pharma Ab · OMXSTO:MOB

Moberg Pharma Ab — Pareto Life Science Seminar 2014

35 slides from Moberg Pharma Ab's conference presentation, Aug 28, 2014

  1. Slide 1: Moberg Pharma AB

    Moberg Pharma AB Combining Commercial and Innovation Excellence to unlock the value of proven molecules Presentation at Pareto Life Science Seminar – August 28, 2014 Peter Wolpert, CEO & Founder 0

  2. Slide 2: Disclaimer

    Disclaimer Statements included herein that are not historical facts are forward-looking statements. Such forward- looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Moberg Pharma’s results could

  3. Slide 3: 2014 TV commercial in the Nordics

    2014 TV commercial in the Nordics 2 2

  4. Slide 4: Moberg Pharma

    Moberg Pharma COMBINING COMMERCIAL AND INNOVATION EXCELLENCE Vision Strategic plan  Build a mid-size Pharma/Consumer  Growth strategy Health company with Sales in: - Organic growth - U.S. and select countries - Innovation engine incl M&A - OTC and select specialty areas  Build value through Brand

  5. Slide 5: Moberg Pharma

    Moberg Pharma COMBINING COMMERCIAL AND INNOVATION EXCELLENCE  Net Sales grew to 178 MSEK (TTM, Q214) - U.S. OTC Sales operations - Products sold in 40+ countries - 30 employees in Sthlm and NJ  Focus in OTC/Dermatology/Topicals - Leading U.S. OTC SKU in Nail Fungus - Superior interrim PII data for

  6. Slide 6: H1 2014 – Highlights and Financials

    CONFIDENTIAL H1 2014 – Highlights and Financials

  7. Slide 7: 2014 Highlights

    2014 Highlights #1 with 25% 58% U.S. Market share last 4w Stronger claims Growth in Direct sales H114 Expanded indication for Nalox in EU 21% 60 million SEK raised in directed share issue EBITDA margin for Commercial operations in H114 BUPI - Pipeline boost Acquisition of phase II asset US expansion

  8. Slide 8: Consecutive quarters of sales growth

    17 consecutive quarters of sales growth Product Sales, TTM, MSEK 200 MSEK 175 150 125 100 75 50 25 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2010 2010 2010 2010 2011 2011 2011 2011 2012 2012 2012 2012 2013 2013 2013 2013 2014 2014 7 7

  9. Slide 9: Majority of revenue from direct OTC sales

    Majority of revenue from direct OTC sales – Strong contribution to earnings from both channels Distribution of revenue, Jan – June 2014 JointFlex Other RoW Sales via 12% 12% 4% distributors Europe 32% Kerasal 22% 16% Nalox/ Direct OTC Kerasal Nail Americas Sales 68% 60% 74% Channels Products Geograp

  10. Slide 10: Rapid increase in sales and EBITDA

    Rapid increase in sales and EBITDA (MSEK) 157 112 106 Milestones 56 Product Sales Net Sales 2011 2012 2013 2014 H1 13 14 13 EBITDA EBITDA -8 -8 -13 EBITDA excluding -16 milestone payments -29 9 9

  11. Slide 11: Commercial Operations

    Commercial Operations

  12. Slide 12: U.S. OTC market is expanding

    U.S. OTC market is expanding A large aging population, steady to increased incidences of conditions and diseases, self care & Rx to OTC switches fuel OTC market growth Total US Sales (billions) $44,3 $42,1 $40,1 $38,4 $37,2 +5.2% +4.9% +3.2% +4.5% 12/25/10 12/24/11 12/22/12 est. 2013 est. 2014 11 So

  13. Slide 13: U.S. OTC market is highly consolidated

    U.S. OTC market is highly consolidated Ten largest retailers account for almost 70% of sales +5.2% +4.9% +3.2% +4.5% 12 Source: IRI. 52 weeks as of May 2013 12

  14. Slide 14: Platform for building Brand Equity in the US

    Platform for building Brand Equity in the US – Cost effective U.S. OTC infrastructure CMOs Sales Force Retailers/Wholesalers Sales and marketing/Brand Management Logistics 13 13

  15. Slide 15: Building a profitable growth portfolio of Brands, Products and Projects

    Building a profitable growth portfolio of Brands, Products and Projects through M&A and internal development Current portfolio Future portfolio Brands +XYZ Products sold ® through partners 15 partners incl Meda, Menarini & Paladin Pipeline MOB-015 BUPI +XY 14 14

  16. Slide 16: Significantly faster growth than the market

    Significantly faster growth than the market Organic growth 2014 H1 (Value), percent Growth driver 31%  Combination of Brand and IP equity: 5% Moberg U.S. U.S. OTC market 15 15

  17. Slide 17: Kerasal Nail – Best selling SKU in its category

    Kerasal Nail™ – Best selling SKU in its category 0%  23% market share increase in 3 years  Available at 30 000 points of sale  New patent pending formulation launched Q114  Market share 25% last 4w  Recent distribution added: 16 16

  18. Slide 18: Kerasal NeuroCream rapidly gains market share

    Kerasal® NeuroCream rapidly gains market share in a niche category with growth potential – Now no 2 SKU  Positive initial response on advertising and the product from consumers and retailers  Walgreens increases distribution  21,000 stores at Walmart, CVS, Walgreens, and Rite Aid  Ca 30 million

  19. Slide 19: Acquisition of three brands from Bayer Healthcare

    Acquisition of three cash-generating brands from Bayer Healthcare in Dec 2013 • Noncore to Bayer Healthcare – no marketing in over 10 years, ca 3m$ in Net Sales • Leverages U.S. OTC platform • Domeboro is a astringent solution that provides fast, soothing itch relief for skin irritations • Vanquish

  20. Slide 20: Vanquish – Launched integrated Marketing plan

    Vanquish – Launched integrated Marketing plan 19 19

  21. Slide 21: Domeboro - Brand modernization

    CONFIDENTIAL Domeboro - Brand modernization New web - Skin Care Center 20 20

  22. Slide 22: Distributor sales

    Distributor sales

  23. Slide 23: Moberg Pharma Global Markets

    Moberg Pharma Global Markets – >20 markets remain to launch under current contracts All markets Kerasal Nail/Nalox/Emtrix Jointflex Kerasal 22

  24. Slide 24: Distributor Sales well positioned for further growth

    Distributor Sales well positioned for further growth Nalox™/Kerasal Nail™  10% growth in Europe – implementation of new stronger claims only started.  Potential for further growth in 2015  Strong sales in Canada as response to launch of consumer advertising,  Market leader with 25% market share

  25. Slide 25: Innovation Engine

    Innovation Engine

  26. Slide 26: Innovation engine

    Innovation engine  8 patent families >100 - MOB015 – Ph II data expected in Sept - BUPI – Ph II expected Sept – Q115 - Kerasal Nail+/Nalox+  Focus to strengthen OTC pipeline BD OPPORTUNITIES EVALUATED IN 2013/14 Acquisitions/inlicensing  Focus on OTC assets for U.S. market 3 ACQUISITIONS LAST 21

  27. Slide 27: MOB-015 – Superior results after 6 months

    MOB-015 – Superior results after 6 months 40% MYCOLOGICAL CURE AFTER 6 MONTHS MOB-015, n=25, Final data in September 2014 26 Source: 1)Moberg Pharma data on file from ongoing phase II study 26

  28. Slide 28: MOB015 interim results compared with marketed topical and oral drugs

    MOB015 interim results are superior to topical drugs on the market and on par with oral terbinafine therapy – but without the safety issues of oral therapy Mycological cure Active Product Company Form at 6 months at 12/15 Comment months Terbinafine MOB-015 Moberg Pharma Topical 40%1) In Sept 2014 25

  29. Slide 29: Acquisition of BUPI lozenge – Oral mucositis is 1st indication

    Acquisition of BUPI lozenge – Oral mucositis is 1st indication 28 28

  30. Slide 30: Acquisition of BUPI assets

    Acquisition of BUPI assets Product & Indication  Bupivacaine lozenge for oral pain relief (mouth and throat)  1st indication: Oral Mucositis in cancer patients. Large unmet need  Other indications: Burning Mouth Syndrome, Sjögren’s syndrome, Upper gastrointestinal endoscopy. Long-term also OTC po

  31. Slide 31: Management and Outlook

    Management and Outlook

  32. Slide 32: Management and Board with strong track record

    Management and Board with strong track record Management experience Board experience McKinsey, AZ, Q-Med, Biogen Idec, Pharmacia/Pfizer, Lundbeck, Genmab, Quintiles, Altaris Alterna, Karolinska Dev Capital, Merrill Lynch, J&J, Barrier Therapeutics, NCH Peter Wolpert Martin Ingman Steve Cagle Mats Pe

  33. Slide 33: The Share last 3 years

    The Share last 3 years (Aug 21 2014) Analysts  Klas Palin, Redeye  Christian Lee, Remium  Additional coverage expected H2 2014 32 32

  34. Slide 34: 20 largest shareholders by June 30, 2014

    CONFIDENTIAL 20 largest shareholders by June 30, 2014 Shareholders No of shares Capital and votes, % ÖSTERSJÖSTIFTELSEN 2 248 478 16,1 SIX SIS AG, W8IMY 890 645 6,4 JPM CHASE NA (Altaris Capital Partners) 825 652 5,9 BURE EQUITY AB (PUBL) 811 151 5,8 FÖRSÄKRINGSAKTIEBOLAGET, AVANZA PENSION 773 472 5

  35. Slide 35: Focus next 12 months

    Focus next 12 months BUILDING A DIFFERENT KIND OF PHARMA COMPANY  Improving EBITDA!  Fuel strong U.S growth - K-Nail and Neurocream launch - Line extensions and new SKUs  Grow Distributor Sales - EU: Extended indication - China registration, SE Asia, Mena  BD focus - US OTC products  MOB-015 fi

Moberg Pharma — Pareto Life Science Seminar 2014 on 6ix